ArticleScientific reports2026
Computational design and immunoinformatics validation of a T cell multi-epitope vaccine targeting glioblastoma stem cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Glioblastoma multiforme is a highly aggressive and lethal primary brain tumor in adults, with a poor prognosis and high recurrence rate driven by glioblastoma stem cells (GSCs). The primary objective of this study is to design and characterize a novel multi-epitope vaccine, Gliostem-MultiVax, targeting GSC-specific antigens to overcome tumor recurrence and treatment resistance. These biomarkers are essential for tumor initiation, progression, resistance to standard treatments, and the recurrence of cancer. Six well-established GSC-specific markers (CD133, CD44, Sox2, Nestin, CD15, and Musashi-1) were selected as antigen sources. Using comprehensive immunoinformatic tools, CD8 + and CD4 + T-cell epitopes were predicted. The epitopes were linked with appropriate linkers and combined with the adjuvant Rv3628 to construct the multi-epitope vaccine. Physicochemical characteristics, population coverage, and 2D and 3D structures of the vaccine were analyzed. Molecular docking and molecular dynamics (MD) simulations were performed to evaluate the interaction model of the vaccine-TLR2 complex. The immune simulation to evaluate the immunogenicity and in silico cloning of the designed vaccine were conducted. Nine CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.